全球新药王落定

Group 1 - The core product Mounjaro, a diabetes treatment, achieved sales of $22.965 billion in 2025, a 99% year-on-year increase, while the weight loss product Zepbound reached $13.542 billion, a 175% increase [2] - Combined sales of the two products totaled $36.507 billion, surpassing Novo Nordisk's semaglutide sales of $36.1 billion, making it the highest-selling drug globally in 2025 [2] - Eli Lilly's total revenue for 2025 reached $65.179 billion, a 44% increase year-on-year, with net profit of $20.64 billion, up 95% [2] Group 2 - The GLP-1 market has been significantly boosted by Novo Nordisk's success with semaglutide, but Eli Lilly's dual-target drug tirzepatide has shown superior weight loss results [3] - Eli Lilly has adopted a strategy of "internal expansion + external collaboration" to meet the high demand for GLP-1 drugs, partnering with WuXi AppTec, which has a strong position in the TIDES sector [3] - WuXi AppTec reported TIDES revenue of 7.84 billion yuan in the first three quarters of 2025, a 121.1% increase, and raised its revenue forecast for 2025 to approximately 45.456 billion yuan, a 15.84% year-on-year growth [4] Group 3 - Eli Lilly has submitted a market application for the oral drug orforglipron for obesity treatment to regulatory authorities in the US and Japan, indicating ongoing innovation in the GLP-1 drug development space [4]